Avillion II (AZ) Revenue and Competitors
Estimated Revenue & Valuation
- Avillion II (AZ)'s estimated annual revenue is currently $7.6M per year.
- Avillion II (AZ)'s estimated revenue per employee is $201,000
Employee Data
- Avillion II (AZ) has 38 Employees.
- Avillion II (AZ) grew their employee count by -10% last year.
Avillion II (AZ)'s People
Name | Title | Email/Phone |
---|---|---|
1 | VP Clinical Development | Reveal Email/Phone |
2 | Head IT | Reveal Email/Phone |
3 | Director Regulatory Affairs | Reveal Email/Phone |
4 | Chief Medical Officer | Reveal Email/Phone |
5 | Senior Director, Clinical Programs | Reveal Email/Phone |
6 | Operations Director | Reveal Email/Phone |
7 | Project Manager | Reveal Email/Phone |
8 | FP&A Manager | Reveal Email/Phone |
9 | Project Manager | Reveal Email/Phone |
10 | Clinical Trial Liaison Manager | Reveal Email/Phone |
Avillion II (AZ) Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $64.5M | 321 | 10% | N/A | N/A |
#2 | $25.5M | 127 | 5% | N/A | N/A |
#3 | $115.6M | 575 | 2% | N/A | N/A |
#4 | $21.7M | 108 | 4% | N/A | N/A |
#5 | $44.8M | 223 | 9% | N/A | N/A |
#6 | $15.1M | 75 | -67% | N/A | N/A |
#7 | $16.1M | N/A | N/A | N/A | |
#8 | $84.4M | 420 | 0% | N/A | N/A |
#9 | $8.8M | 44 | 10% | N/A | N/A |
#10 | $31M | 154 | 28% | N/A | N/A |
What Is Avillion II (AZ)?
A drug development company with an innovative model for Clinical Development. We offer a compelling opportunity to partner late phase therapeutic projects for approval in the EU and US and to accelerate their availability to market.
keywords:N/AN/A
Total Funding
38
Number of Employees
$7.6M
Revenue (est)
-10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.6M | 38 | 27% | N/A |
#2 | $7.1M | 38 | -54% | N/A |
#3 | $6.2M | 38 | -38% | N/A |
#4 | $6.2M | 38 | 31% | N/A |
#5 | $4.4M | 38 | 9% | N/A |